ArticleGynecologic oncology reports2022

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation.

Bárbara Lima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.